RxDoctor Payments Data

Sinnathurai Vasanthakumar, MD

Internal Medicine · St Marys, GANPI 1598714479

Payments from drug & device makers

$11,739in general payments, 2019–2025

Across 709 payments — averaging $16.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$1K
  • Lilly USA, LLC$1K
  • AbbVie$989
  • Amgen$816
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$543
  • plus $6K from 39 others

What the payments were for

  • Food & beverage$11,65399%
  • Education$861%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$11,739 in reported general payments places this provider in the 90th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$140,741
Medicare patients
376
Services billed
2,628

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban161$158,788
MounjaroTirzepatide113$121,755
OzempicSemaglutide100$101,605
HumiraAdalimumab12$81,738
JardianceEmpagliflozin34$39,294
EntrestoSacubitril/Valsartan28$30,298
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$27,073
FarxigaDapagliflozin Propanediol33$24,185
XareltoRivaroxaban34$21,612
TrulicityDulaglutide20$21,187
RybelsusSemaglutide18$18,810
MyrbetriqMirabegron25$18,690
LinzessLinaclotide23$18,472
JanuviaSitagliptin Phosphate16$13,459
CreonLipase/Protease/Amylase13$11,290

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$496$158,788161 claims
Lilly USA, LLCMounjaro, Trulicity$1,050$142,942133 claims
Novo NordiskOzempic, Rybelsus$1,344$120,416118 claims
AbbVieHumira, Linzess, Creon$989$111,50048 claims
Boehringer IngelheimJardiance, Tradjenta$140$48,77049 claims
AstraZenecaFarxiga, Brilinta, Symbicort$1,257$33,92855 claims
GSKTrelegy Ellipta, Breo Ellipta$516$32,38639 claims
NovartisEntresto$391$30,29828 claims
Johnson & JohnsonXarelto$387$21,61234 claims
Astellas Pharma US IncMyrbetriq$425$18,69025 claims
MerckJanuvia$297$13,45916 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$174$5,49611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in St Marys

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →